A Clinical Study to Evaluate the Effects of Estrogen in Healthy Postmenopausal Women
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00820664 |
Recruitment Status :
Completed
First Posted : January 12, 2009
Results First Posted : May 7, 2010
Last Update Posted : January 22, 2016
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Postmenopausal Symptoms | Drug: Comparator: Estrace 0.5 mg Drug: Comparator: Estrace 2 mg Drug: Comparator: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 29 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Diagnostic |
Official Title: | A Randomized Clinical Trial to Evaluate the Effects of Estrogen on Uterine Endometrium in Healthy Postmenopausal Women |
Study Start Date : | December 2008 |
Actual Primary Completion Date : | May 2009 |
Actual Study Completion Date : | May 2009 |
Arm | Intervention/treatment |
---|---|
Active Comparator: 17β-estradiol 2.0 milligrams
Estrace 2.0 mg tablet
|
Drug: Comparator: Estrace 2 mg
2 mg tablets taken once daily for 28 days.
Other Name: Estrace |
Active Comparator: 17β-estradiol 0.5 milligrams
Estrace 0.5 mg tablet
|
Drug: Comparator: Estrace 0.5 mg
0.5 mg tablet taken once daily for 28 days
Other Name: Estrace |
Placebo Comparator: 3
Placebo
|
Drug: Comparator: Placebo
Placebo 0 mg capsule taken once daily for 28 days |
- Immunohistochemistry (IHC) Proliferative Effects Measurement [ Time Frame: 4 weeks ]Ratio of the total number of positively stained cell nuclei to the total number of cell nuclei. Proliferating endometrial cells express the Ki-67 antigen. The ratio was converted to a percent proliferating cells by taking the number of Ki-67 positive stained nuclei in a given field and dividing by the total number of nuclei in that field and multiplying by 100. At least 5 high power fields were scored in this manner and an aggregate percent Ki-67 positive cells was reported. Square root transformation was taken to make it approximately normally distributed for an ANOVA model to apply.
- Mean Gene Expression Intensity After 4 Weeks of Either 0.5 or 2 mg Estrace Compared to Placebo. [ Time Frame: 4 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Patient is a healthy postmenopausal woman less than or equal to 65 years of age with onset of menopause less than or equal to 10 years prior to prestudy visit 1
- Patient has a uterus and no history of uterine bleeding in the past 3 months
- Patient has not had a previous endometrial biopsy within the last 4 weeks
- Patient has had a normal mammogram within the last 11 months
- Patient has had a normal pap-smear within the past 3 years prior to screening
- Patient has had a normal transvaginal ultrasound of the endometrium
- Patient is willing to avoid strenuous physical activity such as strenuous or unaccustomed weight lifting, running, bicycling, etc for the duration of the study
- Patient agrees to not consume grapefruit products beginning approximately 2 weeks prior to the first dose of study drug and throughout the study
- Patient agrees to limit daily consumption of alcohol. During the study, daily alcohol consumption should not be more than 2 glasses
- Patient agrees to limit daily consumption of caffeine. During the study, daily caffeine consumption should not exceed 3 cups of coffee
- Patient is a non-smoker
Exclusion Criteria:
- Patient is mentally or legally incapacitated
- Patient has a history of any first degree relatives with breast or endometrial cancer
- Patient has a history of multiple and/or severe allergies to prescription or non-prescription drugs or food
- Patient has used any type of estrogen or progesterone preparation unless followed by appropriate wash-out periods
- Patient has had surgery, donated approximately 500 mL of blood or has participated in another investigational study within the last 4 weeks
- Patient has a history of deep vein thromboses, coronary artery disease, heart attack or stroke
- Patient is a current user of illegal drugs
- Patient has a history of hypersensitivity to estrogen products
- Patient is unable to refrain from using anti-coagulants

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00820664
Study Director: | Medical Monitor | Merck Sharp & Dohme Corp. |
Responsible Party: | Merck Sharp & Dohme Corp. |
ClinicalTrials.gov Identifier: | NCT00820664 |
Other Study ID Numbers: |
0000-122 2009_505 |
First Posted: | January 12, 2009 Key Record Dates |
Results First Posted: | May 7, 2010 |
Last Update Posted: | January 22, 2016 |
Last Verified: | January 2016 |
Estradiol 3-benzoate Estradiol 17 beta-cypionate Estradiol Polyestradiol phosphate Estrogens Hormones |
Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Contraceptive Agents Reproductive Control Agents Contraceptive Agents, Female |